Ignite Creation Date:
2025-12-25 @ 2:07 AM
Ignite Modification Date:
2025-12-31 @ 7:00 PM
Study NCT ID:
NCT04580160
Status:
COMPLETED
Last Update Posted:
2025-05-15
First Post:
2020-10-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2024-10-01', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D062108', 'term': 'May-Thurner Syndrome'}, {'id': 'D020246', 'term': 'Venous Thrombosis'}], 'ancestors': [{'id': 'D054079', 'term': 'Vascular Malformations'}, {'id': 'D018376', 'term': 'Cardiovascular Abnormalities'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D016491', 'term': 'Peripheral Vascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D000013', 'term': 'Congenital Abnormalities'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D013927', 'term': 'Thrombosis'}, {'id': 'D016769', 'term': 'Embolism and Thrombosis'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'Jgriffin@vespermedical.com', 'phone': '4848926340', 'title': 'Joseph C. Griffin, III', 'organization': 'Vesper Medical'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Summary of adverse events that have been reported through 390 days', 'eventGroups': [{'id': 'EG000', 'title': 'Duo Venous Stent System', 'description': 'Use of the Duo Venous Stent System in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.', 'otherNumAtRisk': 162, 'deathsNumAtRisk': 162, 'otherNumAffected': 102, 'seriousNumAtRisk': 162, 'deathsNumAffected': 2, 'seriousNumAffected': 46}], 'otherEvents': [{'term': 'Blood and lymphatic system disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 6, 'numAffected': 5}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cardiac disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 17, 'numAffected': 12}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Congenital, familial and genetic disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Ear and labyrinth disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Gastrointestinal disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 22, 'numAffected': 19}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'General disorders and administration site conditions', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 44, 'numAffected': 31}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Immune system disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Infections and infestations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 51, 'numAffected': 39}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Injury, poisoning and procedural complications', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 14, 'numAffected': 13}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Investigations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Metabolism and nutrition disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Musculoskeletal and connective tissue disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 47, 'numAffected': 32}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Nervous system disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 23, 'numAffected': 16}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pregnancy, puerperium and perinatal conditions', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Product issues', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Product Issues', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Psychiatric disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Renal and urinary disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 5, 'numAffected': 4}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Reproductive system and breast disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 5, 'numAffected': 4}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Respiratory, thoracic and mediastinal disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 17, 'numAffected': 13}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Skin and subcutaneous tissue disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 14, 'numAffected': 10}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Surgical and medical procedures', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Vascular disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 33, 'numAffected': 27}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Blood and lymphatic system disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cardiac Disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 6, 'numAffected': 5}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Congenital, familial and genetic disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Gastrointestinal disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'General disorders and administration site conditions', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Infections and infestations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 9, 'numAffected': 8}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Injury, poisoning and procedural complications', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Metabolism and nutrition disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Musculoskeletal and connective tissue disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Nervous system disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 5, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pregnancy, puerperium and perinatal conditions', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Product issues', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Product Issues', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Psychiatric disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Renal and urinary disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Reproductive system and breast disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Skin and subcutaneous tissue disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Surgical and medical procedures', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Vascular disorders', 'stats': [{'groupId': 'EG000', 'numAtRisk': 162, 'numEvents': 11, 'numAffected': 9}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days', 'denoms': [{'units': 'Participants', 'counts': [{'value': '159', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Duo Venous Stent System', 'description': 'Use of the Duo Venous Stent System in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.'}], 'classes': [{'categories': [{'measurements': [{'value': '157', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '30 days', 'description': 'Freedom from major adverse events (MAEs) at 30 days post index procedure, as adjudicated by the Clinical Events Committee (CEC) or Core Laboratory, including:\n\n* Device or procedure-related death\n* Device or procedure-related bleed at the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention or blood transfusion of ≥2 units\n* Device or procedure-related venous injury occurring in the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention\n* Major amputation of the target limb\n* Clinically significant pulmonary embolism (PE), confirmed by CT angiography\n* Stent embolization outside of the target vessel\n* Presence of new thrombus within the stented segment requiring surgical or endovascular intervention', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The number of evaluable subjects for the 30 day Primacy Safety Endpoint was 159.'}, {'type': 'PRIMARY', 'title': 'Efficacy - Number of Participants With Primary Patency of Stented Segment at 12 Months', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Duo Venous Stent System', 'description': 'Use of the Duo Venous Stent System in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.'}], 'classes': [{'categories': [{'measurements': [{'value': '119', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '12 months', 'description': 'Primary patency of stented segment at 12 months defined as freedom from:\n\n* Duplex Ultrasound (DUS) core laboratory adjudicated occlusion or stenosis \\>50% within the stented segment. If DUS shows \\>50% stenosis or occlusion, confirmation by diagnostic intravascular ultrasound (IVUS) is required.\n* CEC adjudicated clinically driven target lesion reintervention (CD-TLR) defined as endovascular or surgical procedure for new, recurrent, or worsening symptoms and core lab adjudicated \\>50% stenosis or occlusion within the stented segment confirmed by diagnostic IVUS', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Of the 136 subjects that completed 12-month follow-up, 132 had data evaluable for the 12-month primary efficacy endpoint. The four subjects in question did not complete the 12-month DUS or had a non-diagnostic 12-month DUS.'}, {'type': 'SECONDARY', 'title': 'VCSS Pain Score and Changes in VCSS From Baseline in ITT Patients', 'denoms': [{'units': 'Participants', 'counts': [{'value': '160', 'groupId': 'OG000'}, {'value': '138', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Duo Venous Stent System', 'description': 'Baseline VCSS Pain Score'}, {'id': 'OG001', 'title': 'DUO Venous Stent System', 'description': 'VCSS Pain Score at 12 months'}], 'classes': [{'categories': [{'measurements': [{'value': '2.0', 'spread': '0.8', 'groupId': 'OG000'}, {'value': '0.5', 'spread': '0.8', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '12 months', 'description': 'The Venous Clinical Severity Score (VCSS) system is a scoring system used to categorize nine attributes of venous disease. For this study, only the Pain Score was collected. The levels of pain severity ranged from 0 (none) to 3 (severe).', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Although 136 subjects completed 12-month follow-up, two additional subjects completed 12-month telephone visits during which VCSS data was collected.'}, {'type': 'SECONDARY', 'title': 'Number of ITT Subjects With Primary Assisted Patency at 12 Months', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Duo Venous Stent System', 'description': 'Use of the Duo Venous Stent System in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.'}], 'classes': [{'categories': [{'measurements': [{'value': '124', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '12 months', 'description': 'Primary assisted patency is defined as freedom from DUS core laboratory adjudicated occlusion or stenosis \\>50% within the stented segment following a reintervention due to a \\>50% but \\<100% stenosis. If DUS shows \\>50% stenosis or occlusion, confirmation by diagnostic IVUS is required.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Primary Assisted Patency data is missing for 5/136 subjects that completed 12-month follow-up.'}, {'type': 'SECONDARY', 'title': 'Number of ITT Subjects With Secondary Patency at 12 Months', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Duo Venous Stent System', 'description': 'Use of the Duo Venous Stent System in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.'}], 'classes': [{'categories': [{'measurements': [{'value': '125', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '12 months', 'description': 'Secondary patency at 12 months defined as freedom from DUS core laboratory adjudicated occlusion or stenosis \\>50% within the stented segment following a reintervention due to 100% occlusion. If DUS shows \\>50% stenosis or occlusion, confirmation by diagnostic IVUS is required.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Secondary Patency data is missing for 5/136 subjects that completed 12-month follow-up.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Duo Venous Stent System', 'description': 'Use of the Duo Venous Stent System in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Intent to Treat (ITT) population', 'groupId': 'FG000', 'numSubjects': '162'}]}, {'type': 'COMPLETED', 'achievements': [{'comment': 'Completed 12-month follow-up', 'groupId': 'FG000', 'numSubjects': '136'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '26'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Duo Venous Stent System', 'description': 'Use of the Duo Venous Stent System in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '59.4', 'spread': '15.8', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'BG000'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '60', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '102', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'BG000'}]}], 'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '15', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '134', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '12', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'BMI', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '30.1', 'spread': '5.7', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'kg/m^2', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'CEAP Clinical Assessment', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'BG000'}]}], 'categories': [{'title': 'C0 (No visible or palpable signs of venous disease)', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'C1 (Telangiectasia or reticular veins)', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'C2 (Varicose veins)', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'C2r (Recurrent varicose veins)', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'C3 (Edema)', 'measurements': [{'value': '107', 'groupId': 'BG000'}]}, {'title': 'C4 (Changes in skin and subcutaneous tissue secondary to chronic venous disease)', 'measurements': [{'value': '9', 'groupId': 'BG000'}]}, {'title': 'C4a (Pigmentation or eczema)', 'measurements': [{'value': '21', 'groupId': 'BG000'}]}, {'title': 'C4b (Lipodermatosclerosis or atrophie blanche)', 'measurements': [{'value': '3', 'groupId': 'BG000'}]}, {'title': 'C4c (Corona phlebectatica)', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'C5 (Healed)', 'measurements': [{'value': '8', 'groupId': 'BG000'}]}, {'title': 'C6 (Active venous ulcer)', 'measurements': [{'value': '9', 'groupId': 'BG000'}]}, {'title': 'C6r (Recurrent active venous ulcer)', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "The CEAP (Clinical, Etiological, Anatomical, and Pathophysiological) classification system allows universally uniform diagnosis and comparison of chronic venous disorders. The Clinical aspect of the CEAP classification was used to categorize venous disease. The 'Clinical' signs of venous disease are those that are visible and used to categorize the subject from C0 (No visible or palpable signs of venous disease) to C6r (Recurrent active venous ulcer).", 'unitOfMeasure': 'Participants'}, {'title': 'VCSS Pain', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '160', 'groupId': 'BG000'}]}], 'categories': [{'title': '0 - none', 'measurements': [{'value': '11', 'groupId': 'BG000'}]}, {'title': '1 - mild (occasional, not restricting activity or requiring analgesics)', 'measurements': [{'value': '24', 'groupId': 'BG000'}]}, {'title': '2 - moderate (daily, moderate activity limitation, occasional analgesics)', 'measurements': [{'value': '84', 'groupId': 'BG000'}]}, {'title': '3 - severe (daily, severe limiting activities or requiring regular use of analgesics)', 'measurements': [{'value': '41', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'The Venous Clinical Severity Score (VCSS) system is a scoring system used to categorize nine attributes of venous disease. For this study, only the Pain Score was collected. The levels of pain severity ranged from 0 (none) to 3 (severe).', 'unitOfMeasure': 'Participants', 'populationDescription': 'VCSS Pain Score is missing for two subjects.'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-04-23', 'size': 1115309, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2024-05-15T18:50', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 162}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-11-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'completionDateStruct': {'date': '2025-04-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-07', 'studyFirstSubmitDate': '2020-10-01', 'resultsFirstSubmitDate': '2024-09-04', 'studyFirstSubmitQcDate': '2020-10-01', 'lastUpdatePostDateStruct': {'date': '2025-05-15', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-01-08', 'studyFirstPostDateStruct': {'date': '2020-10-08', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-01-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-12-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days', 'timeFrame': '30 days', 'description': 'Freedom from major adverse events (MAEs) at 30 days post index procedure, as adjudicated by the Clinical Events Committee (CEC) or Core Laboratory, including:\n\n* Device or procedure-related death\n* Device or procedure-related bleed at the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention or blood transfusion of ≥2 units\n* Device or procedure-related venous injury occurring in the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention\n* Major amputation of the target limb\n* Clinically significant pulmonary embolism (PE), confirmed by CT angiography\n* Stent embolization outside of the target vessel\n* Presence of new thrombus within the stented segment requiring surgical or endovascular intervention'}, {'measure': 'Efficacy - Number of Participants With Primary Patency of Stented Segment at 12 Months', 'timeFrame': '12 months', 'description': 'Primary patency of stented segment at 12 months defined as freedom from:\n\n* Duplex Ultrasound (DUS) core laboratory adjudicated occlusion or stenosis \\>50% within the stented segment. If DUS shows \\>50% stenosis or occlusion, confirmation by diagnostic intravascular ultrasound (IVUS) is required.\n* CEC adjudicated clinically driven target lesion reintervention (CD-TLR) defined as endovascular or surgical procedure for new, recurrent, or worsening symptoms and core lab adjudicated \\>50% stenosis or occlusion within the stented segment confirmed by diagnostic IVUS'}], 'secondaryOutcomes': [{'measure': 'VCSS Pain Score and Changes in VCSS From Baseline in ITT Patients', 'timeFrame': '12 months', 'description': 'The Venous Clinical Severity Score (VCSS) system is a scoring system used to categorize nine attributes of venous disease. For this study, only the Pain Score was collected. The levels of pain severity ranged from 0 (none) to 3 (severe).'}, {'measure': 'Number of ITT Subjects With Primary Assisted Patency at 12 Months', 'timeFrame': '12 months', 'description': 'Primary assisted patency is defined as freedom from DUS core laboratory adjudicated occlusion or stenosis \\>50% within the stented segment following a reintervention due to a \\>50% but \\<100% stenosis. If DUS shows \\>50% stenosis or occlusion, confirmation by diagnostic IVUS is required.'}, {'measure': 'Number of ITT Subjects With Secondary Patency at 12 Months', 'timeFrame': '12 months', 'description': 'Secondary patency at 12 months defined as freedom from DUS core laboratory adjudicated occlusion or stenosis \\>50% within the stented segment following a reintervention due to 100% occlusion. If DUS shows \\>50% stenosis or occlusion, confirmation by diagnostic IVUS is required.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['May-Thurner Syndrome', 'Deep Vein Thrombosis', 'Chronic Venous Insufficiency']}, 'descriptionModule': {'briefSummary': 'This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to investigate the safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance goal (PG) established from published, peer reviewed scientific literature related to stenting of iliofemoral venous outflow obstructions.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Males or non-pregnant, non-breastfeeding females ≥18 years of age at the time of consent\n2. Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures\n3. Female subjects of childbearing potential must have a negative pregnancy test within 7 days prior to treatment and must use some form of contraception (abstinence is acceptable) throughout the time of clinical trial exit\n4. Willing and capable of complying with all required follow-up visits\n5. Estimated life expectancy ≥1 year\n6. Subject is ambulatory (use of assistive walking device such as a cane or walker is acceptable)\n7. Body mass index (BMI) \\<40\n8. Clinically significant symptomatic venous outflow obstruction in one iliofemoral venous segment (one limb) per subject, is indicated for venoplasty and stenting, and meets at least one of the following clinical indicators:\n\n 1. Clinical-Etiology-Anatomy-Pathophysiology (CEAP) score ≥3\n 2. Venous Clinical Severity Score (VCSS) pain score ≥2\n 3. Suspected deep vein thrombosis (DVT) with symptoms occurring prior to receiving a DUO Stent\n9. Subject is willing and able to comply with PI recommendation for compression therapy, if required\n10. Presence of unilateral, non-malignant venous obstruction of the common femoral vein (CFV), external iliac vein (EIV), common iliac vein (CIV), or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter and confirmed by venographic or IVUS imaging. The cranial point of the obstruction may extend to the iliac vein confluence of the inferior vena cava (IVC) and the caudal point may be 2mm above either the inflow of the deep femoral (or profunda) or the lesser trochanter, whichever is most cranial\n11. Obstructive lesion(s) able to be treated with continuous stent coverage\n12. Adequate inflow to the target lesion(s) involving at least a patent femoral or deep femoral vein and a landing zone in the CFV free from significant disease requiring treatment\n13. Reference vessel diameter is of adequate size to accommodate the appropriate size stent as measured by IVUS\n14. All vessels from insertion site through target vessel can accommodate a 9F or 10F sheath, depending on the stent size used\n15. Ability to cross interventional devices through target lesion(s)\n16. In DVT subjects, successful treatment of acute thrombus must have occurred prior to receiving any DUO Stents for an underlying obstructive lesion. Successful treatment of acute thrombus is defined as reestablishment of antegrade flow with ≤30% residual thrombus (confirmed by venogram or IVUS) and freedom from bleeding and symptomatic pulmonary embolism (confirmed by imaging). After successful treatment of thrombus is confirmed, eligible obstructive lesion(s) can be treated with a DUO Stent during the same procedure.\n17. All subjects must undergo a SARS-CoV-2 test and have a negative test result within 8 days of the index procedure. If a SARS-CoV-2 test is unavailable due to institution policy, a test shortage, or if there is a delay in test results, the subject must complete the COVID-19 questionnaire and must have answered NO to all questions to be eligible for enrollment. A SARS-CoV-2 test will not be required for enrollment if a subject has received a complete cycle of an authorized COVID-19 vaccine or has documented evidence of a positive COVID-19 antibody test and is asymptomatic and has no long-lasting effects (per PI discretion) from a prior COVID-19 infection.\n18. A measured temperature less than 99.5°F (37.5°C) on the day of the index procedure and no history of fever or feeling feverish within 14 days of the index procedure\n19. No prior history, within 60 days of the index procedure, of a SARS-CoV-2 positive test, or COVID-19 symptoms\n\nExclusion Criteria:\n\n1. Target limb symptoms caused by peripheral arterial disease\n2. Presence of unresolved significant pulmonary embolism prior to use of the DUO Venous Stent System confirmed by chest CT. If subject has documented history of significant pulmonary embolism within the last 6 months, a chest CT is required to confirm significant pulmonary embolism is not currently present.\n3. Presence of IVC obstruction or target venous obstruction that extends into the IVC\n4. Presence of acute DVT located outside target limb\n5. Contralateral venous occlusive disease of the CFV, EIV, and/or CIV, with planned treatment ≤390 days after the index procedure\n6. Uncontrolled or active coagulopathy or known, uncorrectable bleeding diathesis\n7. Coagulopathy causing INR \\>2 which is not amenable to medical treatment\n8. Platelet count \\<50,000 cells/mm3 or \\>1,000,000 cells/mm3 and/or White blood cell (WBC) \\<3,000 cells/mm3 or \\>12,500 cells/mm3\n9. Uncorrected hemoglobin of ≤9 g/dL\n10. Subject is on dialysis or has an estimated glomerular filtration rate (eGFR) \\<30 mL/min. In subjects with diabetes mellitus, eGFR \\<45 mL/min.\n11. History of Heparin Induced Thrombocytopenia\n12. Presence of known aggressive clotting disorders such as Lupus Anticoagulant Disorder, Antiphospholipid antibody syndrome, homozygous gene Factor V Leiden or Prothrombin gene abnormalities, Protein C and S deficiency or Antithrombin deficiency\n13. Known hypersensitivity or contraindication to antiplatelet therapy or anticoagulation, nickel, or titanium\n14. Contrast agent allergy that cannot be managed adequately with pre-medication\n15. Intended concurrent adjuvant procedure (except for venoplasty) such as creation of temporary arteriovenous fistula, femoral endovenectomy or saphenous vein ablation and/or saphenous vein stripping during the index procedure\n16. Subjects who have had any prior surgical or endovascular procedures to the target vessel. Note that subjects who have had successful catheter-directed or mechanical thrombolysis in the target vessel for DVT at least 90 days prior to the index procedure may be included\n17. Planned surgical or interventional procedures of the target limb (except thrombolysis and/or thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in subjects at high risk for pulmonary embolism) within 30 days prior to or 30 days after the index procedure\n18. Planned surgical or interventional procedures for other medical conditions (i.e., not associated with the target limb) 30 days prior to or 30 days after the index procedure\n19. Previous venous stenting of the target limb, the IVC, or contralateral limb if stents extend into the IVC\n20. Iliofemoral venous segment unsuitable for treatment with available sizes of DUO Stent implants\n21. Lesions with intended treatment lengths extending into the IVC\n22. No safe landing zone at or above the profunda femoral confluence\n23. Participating in another investigational study in which the subject has not completed the primary endpoint(s)\n24. Has other comorbidities that, in the opinion of the Investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments'}, 'identificationModule': {'nctId': 'NCT04580160', 'acronym': 'VIVID', 'briefTitle': 'Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System', 'organization': {'class': 'INDUSTRY', 'fullName': 'Vesper Medical, Inc.'}, 'officialTitle': 'Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System', 'orgStudyIdInfo': {'id': 'V-CA-0001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Duo Venous Stent System Implantation', 'interventionNames': ['Device: Duo Venous Stent System']}], 'interventions': [{'name': 'Duo Venous Stent System', 'type': 'DEVICE', 'description': 'Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.', 'armGroupLabels': ['Duo Venous Stent System Implantation']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92868', 'city': 'Orange', 'state': 'California', 'country': 'United States', 'facility': 'St. Joseph Hospital', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '94304', 'city': 'Palo Alto', 'state': 'California', 'country': 'United States', 'facility': 'Stanford University', 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}, {'zip': '06820', 'city': 'Darien', 'state': 'Connecticut', 'country': 'United States', 'facility': 'The Vascular Experts', 'geoPoint': {'lat': 41.07871, 'lon': -73.46929}}, {'zip': '06106', 'city': 'Hartford', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Hartford Hospital', 'geoPoint': {'lat': 41.76371, 'lon': -72.68509}}, {'zip': '20010', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'MedStar Washington Hospital Center', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '33140', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Mount Sinai Medical Center of Florida', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33140', 'city': 'Miami Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Palm Vascular Centers', 'geoPoint': {'lat': 25.79065, 'lon': -80.13005}}, {'zip': '32792', 'city': 'Winter Park', 'state': 'Florida', 'country': 'United States', 'facility': 'University Clinical Research-Deland LLC', 'geoPoint': {'lat': 28.6, 'lon': -81.33924}}, {'zip': '30309', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Piedmont Atlanta Hospital', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Northwestern University', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '52801', 'city': 'Davenport', 'state': 'Iowa', 'country': 'United States', 'facility': 'Midwest Cardiovascular Research Foundation', 'geoPoint': {'lat': 41.52364, 'lon': -90.57764}}, {'zip': '70570', 'city': 'Opelousas', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Cardiovascular Institute of the South', 'geoPoint': {'lat': 30.53353, 'lon': -92.08151}}, {'zip': '48126', 'city': 'Dearborn', 'state': 'Michigan', 'country': 'United States', 'facility': 'Michigan Outpatient Vascular Institute', 'geoPoint': {'lat': 42.32226, 'lon': -83.17631}}, {'zip': '07631', 'city': 'Englewood', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Edgewood Hospital and Medical Center', 'geoPoint': {'lat': 40.89288, 'lon': -73.97264}}, {'zip': '07666', 'city': 'Teaneck', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Holy Name Medical Center', 'geoPoint': {'lat': 40.8976, 'lon': -74.01597}}, {'zip': '10029', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Icahn School of Medicine at Mount Sinai', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10032', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Columbia University Irving Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '11790', 'city': 'Stony Brook', 'state': 'New York', 'country': 'United States', 'facility': 'Stony Brook Medicine', 'geoPoint': {'lat': 40.92565, 'lon': -73.14094}}, {'zip': '28204', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Atrium Health', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '43214', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'The Ohio Health Research Institute', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'University of Pittsburgh Medical Center', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '02906', 'city': 'Providence', 'state': 'Rhode Island', 'country': 'United States', 'facility': 'The Miriam Hospital', 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}, {'zip': '77090', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Houston Healthcare Medical Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '75069', 'city': 'McKinney', 'state': 'Texas', 'country': 'United States', 'facility': 'North Dallas Research Associates', 'geoPoint': {'lat': 33.19762, 'lon': -96.61527}}, {'zip': '78130', 'city': 'New Braunfels', 'state': 'Texas', 'country': 'United States', 'facility': 'Hurricane Cardiology Research', 'geoPoint': {'lat': 29.703, 'lon': -98.12445}}, {'zip': '23507', 'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Sentara Clinical Research', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': '98004', 'city': 'Bellevue', 'state': 'Washington', 'country': 'United States', 'facility': 'Lake Washington Vascular, PPLC', 'geoPoint': {'lat': 47.61038, 'lon': -122.20068}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Medical College of Wisconsin, Vascular & Interventional Radiology, Froedtert Hospital Radiology, Rm 2803', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'zip': '45-401', 'city': 'Opole', 'country': 'Poland', 'facility': 'University Hospital in Opole', 'geoPoint': {'lat': 50.67119, 'lon': 17.92604}}, {'zip': '61-484', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Medical University of Karol Marcinkowski', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Vesper Medical, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}